Valeant Pharmaceuticals International, Inc.

9.25 -0.13(-1.39%) Date:

Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Intl Inc (VRX): Wells Fargo Sees 30% Downside Today, Lowers Range to $7-9

Valeant’s upcoming results are unlikely to reflect its strength in core businesses, according to Wells Fargo analyst

Valeant Pharmaceuticals Intl Inc (VRX) Maintained at Sector Perform at RBC Capital

While Dermatology NRx remained flat Wow, they fell 42.1% YoY on 4-week rolling basis, according to RBC Capital analyst

Valeant Pharmaceuticals Intl Inc (NYSE:VRX): JPMorgan Sees More Than 33% Downside Today, Lowers PT to $10

While Valeant's 1Q set-up appears reasonable, its long-term outlook remains shaky, according to JPMorgan analyst

Here's Why Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Shares Plunged 3% Yesterday

Siliq is unlikely to change Valeant’s dermatology unit fortunes going forward, according to Piper Jaffray analyst

Valeant Pharmaceuticals Intl Inc (VRX): Are the Shares Worth Spending Any Further?

Valeant investors advised to remain cautious ahead given the drugmaker's ongoing circumstances